Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department

Johannes P Borde,1 Winfried V Kern,1 Martin Hug,2 Michaela Steib-Bauert,1 Katja de With,1,3 Hans-Jörg Busch,1,4 Klaus Kaier5

ABSTRACT

Introduction Early initiation of antimicrobial treatment for acute infection is an important task in the emergency department (ED) with a likely impact on the hospital-wide antibiotic use pattern. We implemented an antibiotic stewardship (ABS) programme focused on non-trauma emergency patients at a large university hospital centre targeting broad-spectrum cephalosporin and fluoroquinolone use.

Methods Guidelines and focused discussion groups emphasised reduced prescription of third-generation cephalosporins and fluoroquinolones and encouraged penicillins. Antibiotic consumption expressed as monthly drug density in WHO-Anatomical Therapeutic Chemical defined and locally recommended daily doses (DDD and RDD) per 100 patient days was analysed before (January 2008 to October 2011) and after starting the intervention (January 2012 to October 2013). We performed a before-and-after uncontrolled intervention study using interrupted time-series (ITS) analysis in one ED to investigate ABS intervention-related effects in a quasiexperimental research setting.

Results The mean monthly total antibiotic use density declined from 111 RDD (138 DDD) per 100 patient days before the intervention to 86 RDD (128 DDD) per 100 patient days after starting the intervention. Among the different antibacterial drug classes, the consumption of third-generation cephalosporins showed the largest reduction and dropped significantly by −68% between preintervention and postintervention periods. Using the RDD dataset, ITS confirmed a highly significant postintervention change in level of third-generation cephalosporins (95% CI (−15.2 to −6.31)) and a corresponding increase in the use of aminopenicillin/betalactamase inhibitor formulations (95% CI (4.169 to 9.069)). The drug use densities for fluoroquinolones and for overall antibiotics declined, however, the postinterventional level changes missed statistical significance—overall (95% CI (−39.99 to 0.466)), fluoroquinolones 95% CI (−11.72 to 4.333)).

Conclusions An intensified ABS programme using non-restrictive tools targeting third-generation cephalosporin and fluoroquinolone use in the setting of a large academic hospital emergency medicine department is feasible and effective. The intervention may serve as a model for other emergency medicine departments at hospitals with a similar structure and baseline situation.

INTRODUCTION

Increasing bacterial resistance is a major threat to patients and healthcare systems worldwide. The causes of antibiotic resistance are complex, but include heavy use of antibiotics, both in humans and animals.1 An essential component in the strategies to reduce antimicrobial resistance is to limit overaggressive use of antibiotics in the hospital and primary care setting.2–4 Earlier studies have demonstrated that a reduction in aminoglycoside prescription is linked to a decreasing incidence of Gram-negative resistant bacteria.4,5 Similar findings are reported for the restriction of third-generation cephalosporins6–7 and fluoroquinolones.2 A reduction of infections due to Clostridium difficile, an important cause of hospital-acquired infection, has been described following antibiotic restriction programmes.8

Key messages

What is already known on this subject

Earlier studies have demonstrated that restricting use of third-generation cephalosporins and fluoroquinolones is linked to a decreasing incidence of gram-negative resistant bacteria producing extended beta-lactamases (ESBL), infections due to Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA) infections. The feasibility and sustainability of an antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone consumption, using persuasive tools rather than restrictive tools, has not been evaluated before in the setting of large emergency medicine department.

What this study adds

An intensive antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone prescription, using persuasive rather than restrictive tools, was implemented in a large academic German emergency department. Interrupted time series (TS) analysis in this quasi-experimental research setting demonstrated reduced cephalosporin and fluoroquinolone drug use densities by >20% with sustained performance. Interrupted Time S analysis is the statistic tool of choice to investigate intervention-related effects of ABS programmes in a quasi-experimental research-setting.
**MATERIAL AND METHODS**

**Study design**

Briefly, our study was designed as an ITS to investigate intervention-related effects of ABS programmes in a quasi-experimental research setting. There was no formal calculation on the number of patients needed to include in the study. Antibiotic use data were gathered on a monthly basis from the hospital pharmacy service representing the antibiotic consumption of this clinical department. Written prescriptions handed out for outpatient pharmacies were not included in our study. The number and length of stay of all patients seen in the ED were used to calculate normalised consumption values per 100/patient days. The ethics committee was notified about the trial —formal approval was not required, because the project was based on epidemiological data. Research involving human subjects, human material, specific human or personalised data was not carried out.

**Setting**

Freiburg University Hospital is a 1600-bed academic teaching hospital and tertiary care referral centre, with all major clinical services and departments including renal, lung, heart, haematopoetic stem cell transplant and a level 1 trauma centre. The ED has a 39-bed capacity with four emergency rooms, 10 intermediate care beds equipped with advanced monitoring capabilities and 25 standard care beds. The non-trauma section of the emergency medicine department is operated by three shifts; there are 17 full physician appointments. There are eight on a permanent basis and nine on rotation. During day shifts, there are three internal medicine residents, one internal medicine attending physician and one neurology resident present. During night shifts, there are two internal medicine residents plus one attending physician in service. Each patient is evaluated within 24 h for being admitted or treated on an outpatient basis. In 2013, there were about 38 000 patient contacts in total, 60% trauma patients and 40% medical service patients. Overall, approximately 35% of the patients were admitted for in-hospital treatment. The patients were triaged according to the emergency severity index (ESI). In 2013, 2.5% of the patients were scored as ESI 1, 13% were categorised as ESI 2, 37.5% ESI 3 and 47.5% were assigned to ESI 4 and 5, that is, about 15.5% of all patients required an immediate life-saving intervention or were in a high-risk situation.

**Antibiotic policy and stewardship programme**

Locally consented guidelines for the most frequent indications and acute infections were first available in written formats in 2006. In the following years, the overall hospital-wide antibiotic use density remained stable. However, the use of third-generation cephalosporins and fluoroquinolones increased. Ceftriaxone was one of the most frequently prescribed antibiotic drug and became the first-line drug for treating CAP. Due to increasing rates of enteric bacteria-producing ESBL and vancomycin-resistant enterococci, internal guidelines were revised in October 2011. An intensified ABS programme targeting cefalosporin and fluoroquinolone use on medical wards was initiated and included the medical section of the ED.

The programme included the following components: guideline revision, information, education, intensified infectious disease consultations and standardised treatment protocols. Briefly, we started short-term briefings led by an infectious disease specialist, emphasised the need for infectious disease consultations in the ED by dedicated infectious disease physicians providing academic detailing and feedback. Fluoroquinolone and cephalosporin use, especially the use of third-generation cephalosporins, was discouraged; the use of penicillins was encouraged. The main replacement drug for ceftriaxone was ampicillin/sulbactam. The revised internal guidelines now recommended ampicillin/sulbactam formulations as first-line antibiotics for CAP (the ‘Standard Operating Procedure’ CAP is available from the author on request). Additionally, the use of combination therapy, in particular, including fluoroquinolones, was discouraged. Further, the 2006 established internal infectious disease guidelines covering a broad spectrum of indications were revised and made available in written, pocket-sized formats and accessible on the hospital intranet as well. Our initial idea was to test whether a reduction by >20% in the prescription of both cephalosporins and fluoroquinolones would be possible within 12–24 months, without increasing overall use densities. The number of formal bedside infectious disease emergency consultations remained constant over time, but the number of kerbside and telephone infectious disease consultations increased by 10%.
between preintervention and postintervention, and there were many more briefings and interdisciplinary conferences including infectious disease physicians postintervention.

Outcome data
Antibiotic use data were gathered on a monthly basis from the hospital pharmacy service—before (January 2008 to October 2011) and after starting the intervention (November 2011 to October 2013). Antibiotic use density was expressed as WHO-ATC DDD, and doses adapted to local guidelines RDD, normalised per 100 patient (occupied beds) days to account for discrepancies between DDD for penicillins and commonly RDD in hospital practice. Case-mix indices, the number of patient cases and the number of admissions were obtained from the hospital administration.

Statistical analysis
The effect of the intervention on drug use density (in RDD per 100 patient days) was analysed using ITS with the period between January 2008 through October 2011 as preintervention and November 2011 through October 2013 as postintervention.

RESULTS
The total antibiotic use density decreased in the postintervention period (for overview see figure 2 and table 1). The mean monthly drug use density values preintervention were 111 RDD (138 DDD) per 100 patient days. Following the start of the stewardship programme, these values declined by −22%, if RDD per 100 patient days was considered (−7% for DDD/100) (table 1). However, the postinterventional level changes missed statistical significance in the ITS model (95% CI (−39.99 to 0.466)).

As intended and expected, strong effects associated with the intervention were observed for cephalosporins and penicillins. The consumption of third-generation cephalosporins declined substantially (figure 1, table 1) from 34 to 11 RDD/100 (p<0.001), whereas, the use of ampicillin/sulbactam increased almost 10-fold (p<0.001). The ITS confirmed that most of the

**Table 1** Comparison of mean monthly drug use density values expressed as DDD or RDD per 100 patient days in the medical emergency department preintervention and postintervention (before/after analysis using t test).

<table>
<thead>
<tr>
<th>Drug class</th>
<th>DDD/100</th>
<th></th>
<th>Per cent change</th>
<th>p Value</th>
<th>RDD/100</th>
<th></th>
<th>Per cent change</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-</td>
<td>Post-</td>
<td></td>
<td></td>
<td>Pre-</td>
<td>Post-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>41</td>
<td>31</td>
<td>−24</td>
<td>&lt;0.01</td>
<td>39</td>
<td>22</td>
<td>−42</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3° Cephalosporins</td>
<td>34</td>
<td>11</td>
<td>−68</td>
<td>&lt;0.001</td>
<td>34</td>
<td>11</td>
<td>−68</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1°/2° Cephalosporins</td>
<td>7</td>
<td>20</td>
<td>214</td>
<td>&lt;0.001</td>
<td>4</td>
<td>11</td>
<td>202</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Penicillins</td>
<td>19</td>
<td>39</td>
<td>99</td>
<td>&lt;0.001</td>
<td>18</td>
<td>22</td>
<td>22</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Piperacillin+BLI</td>
<td>14</td>
<td>11</td>
<td>−22</td>
<td>&lt;0.001</td>
<td>16</td>
<td>12</td>
<td>−22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aminopenicillins+BLI</td>
<td>2</td>
<td>22</td>
<td>835</td>
<td>&lt;0.001</td>
<td>1</td>
<td>8</td>
<td>782</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Narrow-spectrum penicillins</td>
<td>3</td>
<td>6</td>
<td>74</td>
<td>0.11</td>
<td>1</td>
<td>2</td>
<td>63</td>
<td>0.11</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>6</td>
<td>3</td>
<td>−47</td>
<td>&lt;0.001</td>
<td>4</td>
<td>2</td>
<td>−49</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>21</td>
<td>17</td>
<td>−22</td>
<td>&lt;0.05</td>
<td>19</td>
<td>14</td>
<td>−26</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>0.5</td>
<td>0.3</td>
<td>−31</td>
<td>0.34</td>
<td>0.4</td>
<td>0.2</td>
<td>−31</td>
<td>0.34</td>
</tr>
<tr>
<td>Glycopeptides</td>
<td>2</td>
<td>1</td>
<td>−67</td>
<td>&lt;0.001</td>
<td>2</td>
<td>1</td>
<td>−67</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Macrolides/Clindamycin</td>
<td>40</td>
<td>32</td>
<td>−20</td>
<td>&lt;0.05</td>
<td>22</td>
<td>19</td>
<td>−12</td>
<td>0.22</td>
</tr>
<tr>
<td>Total</td>
<td>138</td>
<td>128</td>
<td>−7</td>
<td>0.24</td>
<td>111</td>
<td>86</td>
<td>−23</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

BLI, β-lactamase inhibitor; DDD, defined daily doses; RDD, recommended daily doses.

**Figure 1** Drug use densities for third-generation cephalosporins (left scale recommended daily doses/100 patient days) indicating a strong postintervention level change.
Figure 2  Run-charts for all anti-infective substances.
decline of third-generation cephalosporins was, in fact, attributable to the intervention (table 2) with an intervention-related decrease of 15.2 RDD/100 (95% CI (−24.08 to −6.311)). By contrast, with third-generation cephalosporins, other cephalosporins were increasingly prescribed following the intervention. The mean monthly use density values for first-generation and second-generation cephalosporins increased twofold, and this increase was almost entirely associated with the intervention (table 2).

There was no negative impact of the intervention in terms of increasing use of broad-spectrum betalactams (piperacillin/tazobactam and carbapenems), fluoroquinolones or aminoglycosides (table 1, figure 2). The consumption of piperacillin/tazobactam and/or carbapenems showed a decreasing rather than increasing level effect postintervention. Fluoroquinolone use density declined over the observation period (>20%), the level change between preintervention and postintervention for fluoroquinolone use did not reach statistical significance (95% CI (−11.72 to 4.333)).

**DISCUSSION**

We demonstrated that an intensified ABS programme targeting third-generation cephalosporin and fluoroquinolone use in the setting of a large academic hospital ED is feasible and effective. ITS confirmed a highly significant postintervention level change of third-generation cephalosporins and a corresponding increase in the use of aminopenicillin/betalactamase inhibitor formulations. The drug use densities for fluoroquinolones and for overall antibiotics declined, however, both results missed statistical significance. ITS analysis is the statistic tool of choice to investigate intervention-related effects of ABS programmes in a quasi-experimental research setting.19

Our programme was focused on medical service patients including the ED, which is the interface between outpatient and in-hospital care and is, therefore, highly relevant for acute therapeutic decisions, including drug choices in acute infections. We were interested in demonstrating the success of our programme in the ED, since we considered its effect to be essential for having a strong impact on the consumption in other medical service areas of this hospital. The programme itself used established components and tools of ABS interventions, such as revision, consensus and dissemination of local guidelines, education and feedback with discussion. Due to continuing efforts, we achieved sustainability over 2 years, however, changes in hospital-wide resistance patterns and data on possible changes in the incidence of nosocomial infections are not yet available; this is a major limitation of the study. It will be important to evaluate these outcome data ‘medical service-wide’, since the relatively short length of stay in the ED, the time elapsing between antibiotic therapy initiation and selection of a nosocomial superinfection with resistant micro-organisms makes it difficult to show a within-department impact on such endpoints. The present study is another example for the feasibility of ABS interventions in acute care hospitals, even in the setting of a ‘high throughput’ department. Many previous studies have focused on reduced cephalosporin and fluoroquinolone prescriptions and have shown variable results regarding overall consumption, effects on bacterial resistance and *C difficile* infections.14 17 It remains unknown how large, radical and how sustained the reduction of cephalosporins needs to be in order to exert durable effects on bacterial resistance and *C difficile* infections. Further, it is worth to speculate, which of the ‘replacement’ drug classes are optimal or rather negatively interfere with potential positive ecological effects in ABS programmes that successfully reduce cephalosporin prescriptions. We believe that more experience, with targeted ABS programmes

### Table 2

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Baseline Trend</th>
<th>Preintervention Effect Change</th>
<th>Postintervention Effect Change</th>
<th>Constant</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminopenicillin</td>
<td>−0.0099</td>
<td>(−0.0096 to 0.0019)</td>
<td>(−0.0065 to 0.0097)</td>
<td>0.0447</td>
<td>10</td>
</tr>
<tr>
<td>CEPH</td>
<td>−0.174</td>
<td>(−0.207 to −0.141)</td>
<td>(−0.092 to −0.255)</td>
<td>−0.3457</td>
<td>10</td>
</tr>
<tr>
<td>3GC</td>
<td>−0.218</td>
<td>(−0.253 to −0.183)</td>
<td>(−0.187 to −0.311)</td>
<td>−0.3971</td>
<td>10</td>
</tr>
<tr>
<td>2GC</td>
<td>−0.446</td>
<td>(−0.517 to −0.375)</td>
<td>(−0.397 to −0.535)</td>
<td>0.0927</td>
<td>10</td>
</tr>
<tr>
<td>Carbapenem</td>
<td>−0.0324</td>
<td>(−0.038 to −0.027)</td>
<td>(−0.019 to −0.049)</td>
<td>−0.4480</td>
<td>10</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>−0.173</td>
<td>(−0.207 to −0.139)</td>
<td>(−0.151 to −0.203)</td>
<td>0.0107</td>
<td>10</td>
</tr>
<tr>
<td>Total</td>
<td>−0.3971</td>
<td>(−0.436 to −0.358)</td>
<td>(−0.355 to −0.459)</td>
<td>−0.3923</td>
<td>10</td>
</tr>
</tbody>
</table>

95% CIs are shown in brackets; *p<0.05, †p<0.01, **p<0.001.
and controlled before-and-after studies is needed to address these questions properly.

Our study has several limitations. We did not use a control department against which the observed trend changes could be evaluated, and it cannot be excluded that there were some unrelated changes occurring independent from the intervention. Internal controls were unavailable, due to the unique nature of a single ED at this hospital and its influence on the prescribing on wards to which the patients were admitted. Second, although case-mix indices remained similar throughout the observation period, we cannot be sure that disease severity and the distribution of admission diagnoses remained unchanged over time. Third, we did not systematically follow-up individual patients and, therefore, cannot provide data confirming similar patient outcomes preintervention and postintervention, or data regarding intervention adherence and prescription quality. In an analysis of medical service-wide data from January 2008 to March 2013, we documented unchanged case-mix indices, discharge statistics, including in-hospital mortality and time-to-discharge, respectively, with length-of-hospital-stay. From March 2013 to October 2013, these crude outcome estimates remained, furthermore, roughly unchanged. We, therefore, believe that adverse outcomes of our intervention are very unlikely, although there are no specific data available on the ED level.

We were somehow surprised to see a decreasing use of carbapenems and broad spectrum pencillins (BSPs) (piperacillin/tazobactam), with significant postinterventional level changes in the ITS. These drug classes were not primary target drugs of our intervention. We hypothesise that the decreasing use density of this non-target drug classes were the results of facilitated general discussions and ward rounds with dedicated infectious disease consultants. We used persuasive rather than restrictive tools to alter the antibiotic policy in the department and were able to achieve our pursued reduction of cephalosporins and fluoroquinolones by >20%, however, the level change of fluoroquinolone prescriptions was not significant.

Of note, a small trend of fewer fluoroquinolone prescriptions was already observed prior to the programme initiation. This trend might, in part, have been related to a decision taken early in 2011 to abandon fluoroquinolone prophylaxis in haematology-oncology patients and was then intensified by reducing combination therapies including fluoroquinolones postintervention. We speculate, that fluoroquinolone consumption has reached a baseline usage in the framework of unaltered local guidelines for UTI, which can further be influenced only by specifically addressing a change in guidelines for this indication. The focus on persuasive rather than restrictive tools may be important to mention since drug restriction in the emergency or intensive care setting might have been more effective, but would not have been accepted in our hospital. Non-restrictive methods to alter antibiotic policies and to influence rates of antimicrobial resistance appear to work. However, we hypothesise that the time needed to achieve the defined goals might be longer.19

CONCLUSION

In conclusion, an intensified ABS programme using non-restrictive methods targeting third-generation cephalosporin and fluoroquinolone use in the setting of a large academic hospital ED is feasible and effective. This intervention may serve as a model for other EDs at hospitals with a similar structure and baseline situation.

Contributors JPB wrote the manuscript, he was involved in the ID consultant service and performed descriptive statistical analysis of the data. KK did all advanced statistical work and drafted the statistical section of the manuscript. MS-B designed and adopted the database system for ABS purposes. H-JB implemented and discussed internal guidelines for the emergency medicine department. MH provided prescription and consumption data from the pharmacy service. WVK and KdW were planning the project and designed the ABS interventions. WVK supervised the clinical ID consultant service.

Funding This study was supported in part by internal funds from the Department of Medicine. WVK and KdW were supported in part by a grant from the Federal Ministry of Health (BMG grant IAS-2011-25115SB340).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

20 Robinson HL, Robinson PC, Whitty M. Poor Compliance with Community-Acquired Pneumonia Antibiotic Guidelines in a Large Australian Private Hospital Emergency


